Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 tasquinimod versus placebo in metastatic castration-resistant prostate cancer
NL-OMON41396Phase 3Active, not recruiting
- Sponsor
- Active Biotech AB
- Start
- Nov 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in metastatic castration-resistant prostate cancer (mCRPC) comparing Tasquinimod with Placebo (2 arms). Primary endpoint: Progression-free survival. Started Nov 2011; status: active, not recruiting.
02
Drugs
tasquinimod
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NL-OMON41396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41396.